BR112015023651A2 - expressão aumentada de proteínas de picornavírus - Google Patents

expressão aumentada de proteínas de picornavírus

Info

Publication number
BR112015023651A2
BR112015023651A2 BR112015023651A BR112015023651A BR112015023651A2 BR 112015023651 A2 BR112015023651 A2 BR 112015023651A2 BR 112015023651 A BR112015023651 A BR 112015023651A BR 112015023651 A BR112015023651 A BR 112015023651A BR 112015023651 A2 BR112015023651 A2 BR 112015023651A2
Authority
BR
Brazil
Prior art keywords
increased expression
terminal signal
immunogenic polypeptides
proteins
picornavirus
Prior art date
Application number
BR112015023651A
Other languages
English (en)
Inventor
J Massare Michael
Original Assignee
Novavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novavax Inc filed Critical Novavax Inc
Publication of BR112015023651A2 publication Critical patent/BR112015023651A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/135—Foot- and mouth-disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo “expressão aumentada de proteínas de picornavírus” a invenção proporciona proteínas de fusão que contenham peptídeos de sinal n-terminal fundidos com polipeptídeos imunogênicos. os polipeptídeos imu-nogênicos pode ser a partir de vírus, bactérias ou fungos. a invenção também pro-porciona uma expressão elevada dos polipeptídeos imunogênicos utilizando o pep-tídeo de sinal n-terminal. os peptídeos de sinal n-terminal aumentam a síntese da proteína, particularmente quando a proteína não é nem um peptídeo secretor nem transmembranar. as proteínas de fusão podem ser utilizadas para diagnosticar do-enças e para induzir respostas imunitárias.
BR112015023651A 2013-03-15 2014-03-10 expressão aumentada de proteínas de picornavírus BR112015023651A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361790114P 2013-03-15 2013-03-15
PCT/US2014/022399 WO2014150150A1 (en) 2013-03-15 2014-03-10 Enhanced expression of picornavirus proteins

Publications (1)

Publication Number Publication Date
BR112015023651A2 true BR112015023651A2 (pt) 2017-10-24

Family

ID=50391490

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015023651A BR112015023651A2 (pt) 2013-03-15 2014-03-10 expressão aumentada de proteínas de picornavírus

Country Status (13)

Country Link
US (1) US20140271697A1 (pt)
EP (1) EP2970984A1 (pt)
JP (1) JP2016512680A (pt)
KR (1) KR20150139528A (pt)
CN (1) CN105209620A (pt)
AU (1) AU2014237485A1 (pt)
BR (1) BR112015023651A2 (pt)
CA (1) CA2904382A1 (pt)
IL (1) IL241248A0 (pt)
MX (1) MX2015011931A (pt)
RU (1) RU2015143684A (pt)
SG (1) SG11201507253XA (pt)
WO (1) WO2014150150A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111925423B (zh) * 2014-11-07 2022-08-19 普莱柯生物工程股份有限公司 一种抗o型口蹄疫的疫苗组合物及其制备方法和应用
CN108367066B (zh) * 2015-09-10 2023-08-11 台湾地区“中央研究院” 包括类病毒颗粒及新型佐剂的禽流感疫苗组合物
KR20180132742A (ko) 2016-04-11 2018-12-12 바이오제네시스 바고 우루과이 에스.에이. 바이러스 질환을 위한 범용 백신

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ219515A (en) * 1987-02-10 1989-09-27 Wellcome Found Fusion proteins comprising influenza virus ha and a nonnatural antigenic epitope
CN1408434A (zh) * 2002-09-16 2003-04-09 复旦大学 抗家畜口蹄疫的多肽和dna联合疫苗及其制备方法
WO2009020236A2 (en) * 2007-08-07 2009-02-12 Educational Foundation Jichi Medical University Baculoviral vectors with a dual vertebrate and baculovirus promoter controlling an immunogenic fusion gene
CN101993498B (zh) * 2008-10-06 2013-02-13 浙江诺倍威生物技术有限公司 腺病毒载体禽流感重组疫苗
FR2950350B1 (fr) * 2009-09-24 2013-12-13 Centre Nat Rech Scient Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations
AR083533A1 (es) * 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
GB201111183D0 (en) * 2011-06-30 2011-08-17 Animal Health Inst Peptide

Also Published As

Publication number Publication date
EP2970984A1 (en) 2016-01-20
MX2015011931A (es) 2016-04-07
CN105209620A (zh) 2015-12-30
WO2014150150A1 (en) 2014-09-25
CA2904382A1 (en) 2014-09-25
SG11201507253XA (en) 2015-10-29
RU2015143684A (ru) 2017-04-27
AU2014237485A1 (en) 2015-10-22
KR20150139528A (ko) 2015-12-11
US20140271697A1 (en) 2014-09-18
JP2016512680A (ja) 2016-05-09
IL241248A0 (en) 2015-11-30

Similar Documents

Publication Publication Date Title
BR112016020368A2 (pt) proteínas fc multiméricas
TW201613958A (en) MIC-1 fusion proteins and uses thereof
CL2018000226A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
PE20211272A1 (es) POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
GT201200271A (es) Proteínas que se unen al tnf-a
CR20140140A (es) Proteinas de fusión para el tratamiento de desordenes metabolicos
BR112015023105A2 (pt) construto de imunógeno de peptídeo a?, composições, anticorpo e usos de um construto ou combinação de imunógeno de peptídeo a?
EA201491049A1 (ru) Противораковый слитый белок
WO2015020913A3 (en) Influenza hemagglutinin proteins and methods of thereof
BR112012027055A8 (pt) agente estabilizante para proteínas farmacêuticas.
MX2017014730A (es) Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3).
BR112014026531A2 (pt) proteínas de ligação de antígeno ligando cd30 humano
EA201690159A1 (ru) Способы и композиции для лечения рака
MX2021012047A (es) Polipeptidos de fusion de serpina y metodos para utilizar los mismos.
EP4272750A3 (en) Protein antigens that provide protection against pneumococcal colonization and/or disease
PH12014502352A1 (en) Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition
BR112014012460A2 (pt) proteínas recombinantes e seus usos terapêuticos
EA201491277A1 (ru) Противораковый слитый белок
EA201692279A1 (ru) Способ уменьшения иммуногенности белка и пептида
MD20150109A2 (ro) Construcţii proteice mitocondriale şi utilizările acestora
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
EA201792608A2 (ru) Применение белков p3 бактериофага в качестве агентов, связывающих амилоид
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]